维普期刊资源整合服务平台（V6.5）

37篇 您的检索式：作者名="Maddox AM"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Improvement in symptoms and quality of life for advanced non-small-cell lung cancer patients receiving ZD1839 (Iressa) in IDEAL 2显示文摘	Natale RB Skarin AT Maddox AM	2002	Proc Annu Meet Am Soc Clin Oncol2002，21，：	1
2	Selective oral epidermal grow factor tyrosine kinase inhbitor ZD1839 is generally well-tolerated and has activity in non- small-cell lung cancer and other solid tumors: results of a phase Ⅰ trial显示文摘	Herbst RS Maddox AM Rochenberg ML	2002	J Clin Oncol2002，20，18：	1
3	Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors :results of a phase I trial 显示文摘	Herbst RS Maddox AM Rothenberg ML	2002	J Clin Oncol2002，20，18：	1
4	Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non- small cell lung cancer and other solidtumors: results of a phase I trial显示文摘	Herbst RS Maddox AM Rothenberg ML	2002	J Clin Oncol2002，20，38：	1
5	Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small cell lung cancer and other solid tumours: results of a phase I trial 显示文摘	Herbst RS Maddox AM Rothenberg ML	2002	J Clin Oncol2002，20，18：	1
6	Selecive oral ep idermall growth factor recep tot tyro sine kinase inhibitor ZP1839 is generally well-to lera ted and has activity in non-small-cell lung cancer and other solid tumors: resalts of a phase Itrial显示文摘	Herdst RS Maddox AM Rothenberg ML	2002	J Clin Oncol2002，10，18：	1
7	Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD 1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors:results of a phase Ⅰ trial显示文摘	Herbst RS Maddox AM Rothenberg ML	2002	J Clin Oncol2002，20，18：	1
8	Nitric oxide mediatesrelative airway hyporesponsiveness to lipopolysaccharide insurfactant protein A-deficient mice显示文摘	Pastva AM Walker JK Maddox LA	2011	Am J Respir Cell MolBiol2011，44，2：	1
9	Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non- small cell lung cancer and other solid tumors: results of a phase Ⅰ trial显示文摘	Herbst RS Maddox AM Rothenberg ML	2002	Clin Oncol2002，20，18：	1
10	Selective oral epidermal growth factor receptor tyroslne kinase inhibitor ZDl839 is generally well tolerated and has activity in non-small cell lung cancer and other solid tumors:results of a phase Ⅰ trial显示文摘	Herbst RS Maddox AM Rothenberg ML		0，，：	1
11	Nitric oxide mediatesrelative airway hyporesponsiveness to lipopolysaccharide insurfactant protein A-deficient mice显示文摘	Pastva AM Walker JK Maddox LA	2011	Am J Respir Cell MolBiol2011，44，2：	1
12	Nitric oxide mediates relative airway hyporesponsiveness to lipopolysaccharide in surfactant protein A - deficient mice 显示文摘	Pastva AM Walker JK Maddox LA	2011	Am J Respir Cell Mol Biol2011，44，2：	1
13	Selenium deficiency alters the lipoxygense pathyway and mitogenic response in bovine lymphocytes显示文摘	Cao YZ Maddox J Mastro AM	1992	J Nutr1992，122，：	1
14	Selective oral epidermal growth factor receptor tyrosine kinase inhibitor,ZDl839 is generally well tolerated and has activity in non-small-cell lung Cancer and other solid tumors:results of a phase I trial显示文摘	Herbst RS Maddox AM Rothenberg ML	2002	J Clin Oncol2002，20，18：	1
15	Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small cell lung cancer and Other solid tumors: results of a phase Ⅰ trial显示文摘	Herbst RS Maddox AM Rothenberg ML	2002	J Clin Oncol2002，20，18：	1
16	显示文摘	Natale RR Skarin AT Maddox AM	2002	Proc Am Soc Clin Oncol2002，21，29：	1
17	Improvement in symptoms and quality of life for advanced non-small-ceil lung cancer patients receiving ZD1839 ('Iressa') in IDEAL 2 显示文摘	Natale RR Skarin AT Maddox AM	2002	Proc Am Soc Clin Oncol2002，21，：	1
18	Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors:results of a phase Itrial显示文摘	Herbst RS Maddox AM Rot henberg ML	2002	Clin Oncol2002，20，18：	1
19	Selective oralepidermal growth factor receptor tyrosine kinase inhibitor ZD1839is generally well-tolerated and has activity in non-small-cell lungcancer and other solid tumors:results of a phaseⅠtrial显示文摘	Herbst RS Maddox AM Rothenberg ML	2002	ClinOncol2002，20，：	1
20	Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non- small-cell lung cancer and other solid tumors: results of a phase I trial 显示文摘	Herbst RS Maddox AM Rothenberg ML	2002	J Clin Oncol2002，20，18：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示